<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01581775</url>
  </required_header>
  <id_info>
    <org_study_id>10-VIN-122</org_study_id>
    <nct_id>NCT01581775</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Divalproex Sodium ER Tablets 500 mg of Dr. Reddy's Under Fasting Conditions</brief_title>
  <official_title>Open Label, Balanced, Randomized, Single-dose, Crossover Oral Bioequivalence Study of Divalproex Sodium ER Tablets 500 mg of Dr. Reddy's and Depakote ER 500 mg Tablets of Abbott Laboratories, in Healthy Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the bioequivalence between Divalproex Sodium ER
      Tablets 500 mg of Dr. Reddy's and Depakote ER 500 mg Tablets of Abbott Laboratories in
      healthy, adult, human subjects, under fasting conditions and to monitor adverse events and
      ensure the safety of subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, balanced, randomized, two-treatment, two-sequence, two-period, single-dose,
      crossover oral bioequivalence study of Divalproex Sodium Extended Release Tablets 500 mg of
      Dr. Reddy's Laboratories Limited, and Depakote ER 500 mg mg Tablets of Abbott Laboratories in
      healthy, adult, human subjects, under fasting conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve (AUC)</measure>
    <time_frame>Pre-dose 1 hour, 1.50, 3, 4.50, 6, 7.50, 9, 10.50, 12, 13.50, 15, 16.50, 18, 19.50, 21, 22.50, 24, 25.50, 27, 32, 36, 48, 60, 72, 96 hours post-dose.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Divalproex Sodium ER Tablets, 500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Divalproex Sodium ER Tablets, 500 mg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Depakote ER Tablets, 500 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Depakote ER Tablets, 500 mg of Abbott Laboratories</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Divalproex Sodium</intervention_name>
    <description>Divalproex Sodium ER Tablets, 500 mg</description>
    <arm_group_label>Divalproex Sodium ER Tablets, 500 mg</arm_group_label>
    <arm_group_label>Depakote ER Tablets, 500 mg</arm_group_label>
    <other_name>Depakote</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The subjects were selected for study participation, if they met the following criteria:

          1. Subjects aged between 18 and 45 years (both inclusive).

          2. Subjects' weight within normal range according to normal values for Body Mass Index
             (18.5 to 24.9 kg/m2) with minimum of 50 kg weight.

          3. Subjects with normal health as determined by personal medical history, clinical
             examination and laboratory examinations within the clinically acceptable reference
             range.

          4. Subjects having normal 12-lead electrocardiogram (ECG).

          5. Subjects having normal chest X-Ray (P/A view) whose X-Ray was taken not more than 6
             months prior to the dosing of Period 01.

          6. Subjects having negative urine screen for drugs of abuse (including amphetamines,
             barbiturates, benzodiazepines, marijuana, cocaine, and morphine).

          7. Subjects having negative alcohol breath test.

          8. Subjects willing to adhere to the protocol requirements and to provide written
             informed consent.

        Exclusion Criteria:

        The subjects were excluded from the study, if they met any of the following criteria:

          1. Hypersensitivity to Divalproex or related class of drugs.

          2. History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             gastrointestinal, endocrine, immunological, dermatological, neurological or
             psychiatric disease or disorder.

          3. Any treatment which could bring about induction or inhibition of hepatic microsomal
             enzyme system within 1 month of the study starting.

          4. History or presence of significant alcoholism or drug abuse.

          5. History or presence of significant smoking (more than 10 cigarettes or beedi's/day).

          6. History or presence of asthma, urticaria or other significant allergic reactions.

          7. History or presence of significant gastric and/or duodenal ulceration.

          8. History or presence of significant thyroid disease, adrenal dysfunction, organic
             intracranial lesion such as pituitary tumor.

          9. History or presence of cancer.

         10. Difficulty with donating blood.

         11. Difficulty in swallowing solids like tablets or capsules.

         12. Use of any prescribed or OTC medication during last two weeks prior to dosing in
             period 01.

         13. Major illness during 3 months before screening.

         14. Participation in a drug research study within past 3 months.

         15. Donation of blood in the past 3 months before screening.

         16. Consumption of grapefruit juice, xanthine-containing products, tobacco containing
             products or alcohol for within 48 hours prior to dosing.

         17. Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.

         18. History or presence of significant easy bruising or bleeding.

         19. History or presence of significant recent trauma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Gunjan Shah, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Veeda Clinical Research, India</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veeda Clinical Research, India</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujrat</state>
        <zip>380 015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <last_update_submitted>April 19, 2012</last_update_submitted>
  <last_update_submitted_qc>April 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Divalproex Sodium</keyword>
  <keyword>Crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

